Biotech News

New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*

Lifevantage (LFVN)Lifevantage2026-10-29 20:05 ESTCompany update

SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environmental toxins—pollution, microplastics, ultra-processed foods, hormone

Related news

LFVNLifevantage2026-04-09 20:05 EST

LifeVantage to Participate in Water Tower Research Insights Conference on Wednesday, April 15, 2026

LFVNLifevantage2026-10-26 20:05 EST

LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026

View all latest news

Lifevantage

Direct-Selling Wellness Company LifeVantage develops and markets nutritional supplements and personal-care products through a network of independent consultants. Nutrigenomics Positioning The company's products are marketed around activation of cellular pathways associated with antioxidant response, metabolism and healthy aging rather...

Recent company news

LFVNLifevantage2026-10-29 20:05 EST

New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*

LFVNLifevantage2026-10-26 20:05 EST

LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026

LFVNLifevantage2026-10-12 20:05 EST

LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LFVNLifevantage2026-09-18 12:00 EST

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026

LFVNLifevantage2026-08-27 20:05 EST

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026

Stock data

Close: 5.05 USD
Market cap: 108.75M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States